BestGrowthStocks.com Issues a Comprehensive Analysis of Avalo Therapeutics

BestGrowthStocks.com Issues a Comprehensive Analysis of Avalo Therapeutics

–News Direct–

NEW YORK, NY / NewsDirect / September 27th, 2023 / Best Growth Stocks, a leading independent equity research and corporate access firm focused on finding and reporting on the best growth stocks utilizing exclusive ai-assisted research recently issued an extensive analysis on Avalo Therapeutics Inc a clinical-stage biotechnology company focused on the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network.

Avalo Therapeutics Inc (NASDAQ: AVTX) recently announced the elimination of $35 million in debt paving the way for future growth and innovation.

Best Growth Stock's full report breaks through the noise and offers a full comprehensive and easy-to-understand analysis of Avalos securities, recent events, earnings, pipeline, and more.

Access this full report: https://bestgrowthstocks.com/access-avtx-analysis/ (copy and paste to browser may be required)

About Avalo Therapeutics

Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network.

LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with HSV Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes; also referred to as TNFSF14) is an immunoregulatory cytokine. LIGHT and its signaling receptors, HVEM (TNFRSF14), and lymphotoxin receptor (TNFRSF3), form an immune regulatory network with two co-receptors of herpesvirus entry mediator, checkpoint inhibitor B and T Lymphocyte Attenuator (BTLA), and CD160 (the LIGHT-signaling network). Accumulating evidence points to the dysregulation of the LIGHT-signaling network as a disease-driving mechanism in autoimmune and inflammatory reactions in barrier organs. Therefore, we believe reducing LIGHT levels can moderate immune dysregulation in many acute and chronic inflammatory disorders.

Avalo has an experienced leadership team with decades of successful leadership in drug development in the biotech and pharma industries. The team is led by Dr. Garry Neil, MD, Chief Executive Officer and Chairman of the Board, who brings a wealth of experience leading teams who have successfully brought drugs to the market, including serving as Group President, Pharmaceutical R&D and Corporate VP of Science & Technology at Johnson & Johnson. Additionally, Dr. Neil served as Chairman of the Board of Arena Pharmaceuticals Inc., which was acquired by Pfizer Inc. for $6.7 billion in March of 2022. Dr. Neil currently serves on the board of directors of Celldex Therapeutics.

For more information about Avalo, please visit https://www.avalotx.com/.

Investor Inquiries

Christopher Sullivan, CFO

Avalo Therapeutics, Inc.

ir@avalotx.com

410-803-6793

About Best Growth Stocks

Best Growth Stocks is a leading independent equity research and corporate access firm focused on finding and reporting on the best growth stocks utilizing our exclusive ai-assisted research. BGS is also a financial news provider, focused on giving investors direct access to CEOs of promising, publicly-traded companies, and market experts. Our CEO interviews aim to answer the questions that rest on the minds of current and future shareholders. Not to be construed as financial advice. Consult with a licensed financial advisor prior to any financial decisions.

Media Contact

Best Growth Stocks

Steve Macalbry, Senior Editor

Editor@BestGrowthStocks.com

SOURCE: BestGrowthStocks.Com

Contact Details

Best Growth Stocks

Steve Macalbry

Editor@bestgrowthstocks.com

View source version on newsdirect.com: https://newsdirect.com/news/bestgrowthstocks-com-issues-a-comprehensive-analysis-of-avalo-therapeutics-129571058

Avalo Therapeutics Inc

comtex tracking

COMTEX_441050985/2655/2023-09-27T08:00:07

Post Disclaimer

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No DigiShor journalist was involved in the writing and production of this article.